{"transactions":[{"id":4636916,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-10-07T20:00:06.000Z","date":"2026-10-05","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":27.6968,"value":830904.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be\nfurnished to the SEC staff upon request."}],"balance_after":782881,"source":{"system":"sec-edgar","filing":"0001193125-26-416950","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526416950/ownership.xml","form_type":"4"}},{"id":746625,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T20:00:06.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":24372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":24372,"derivative":{"exercise_price":14.31,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":24372},"source":{"system":"sec-edgar","filing":"0001193125-26-261638","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000119312526261638/ownership.xml","form_type":"4"}},{"id":939364,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-14T21:08:37.000Z","date":"2026-01-12","kind":"gift","planned":false,"acquired":false,"shares":17780,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift for no consideration."}],"balance_after":812881,"source":{"system":"sec-edgar","filing":"0001193125-26-012921","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000119312526012921/ownership.xml","form_type":"4"}},{"id":1118352,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-09T20:06:38.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":5.05,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-25-083713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017025083713/ownership.xml","form_type":"4"}},{"id":1293309,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-28T21:55:45.000Z","date":"2025-01-24","kind":"gift","planned":false,"acquired":false,"shares":27910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a bona fide gift for no consideration."},{"field":"shares","element":"transactionShares","label":"F2","text":"These shares of common stock remain subject to a lock-up agreement pursuant to which they cannot be sold prior to March 11, 2025 without the consent of Leerink Partners LLC, subject to certain exceptions."}],"balance_after":830661,"source":{"system":"sec-edgar","filing":"0000950170-25-009913","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017025009913/ownership.xml","form_type":"4"}},{"id":1414255,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-05T23:26:07.000Z","date":"2024-09-03","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":2.198,"value":219800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.14 to $2.235. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":858571,"source":{"system":"sec-edgar","filing":"0000950170-24-104186","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017024104186/ownership.xml","form_type":"4"}},{"id":1487243,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:44:55.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.76,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-070778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017024070778/ownership.xml","form_type":"4"}},{"id":1668342,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-29T21:38:24.000Z","date":"2024-01-25","kind":"gift","planned":false,"acquired":false,"shares":9100,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":758571,"source":{"system":"sec-edgar","filing":"0000950170-24-008347","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017024008347/ownership.xml","form_type":"4"}},{"id":1676714,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-18T21:50:08.000Z","date":"2024-01-16","kind":"gift","planned":false,"acquired":false,"shares":94350,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":767671,"source":{"system":"sec-edgar","filing":"0000950170-24-005437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000095017024005437/ownership.xml","form_type":"4"}},{"id":1859193,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T23:46:15.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":16985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":16985,"derivative":{"exercise_price":26.25,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":16985},"source":{"system":"sec-edgar","filing":"0000899243-23-015410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323015410/doc4.xml","form_type":"4"}},{"id":1881381,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-23T21:16:50.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":false,"shares":8733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."}],"balance_after":0,"derivative":{"exercise_date":"2023-05-18","underlying":"Common Stock","underlying_shares":8733},"source":{"system":"sec-edgar","filing":"0001600620-23-000019","document":"wk-form4_1684876599.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000160062023000019/wk-form4_1684876599.xml","form_type":"4"}},{"id":1881380,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-23T21:16:50.000Z","date":"2023-05-18","kind":"exercise","planned":false,"acquired":true,"shares":8733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of Issuer Common Stock. The RSUs have no expiration date."}],"balance_after":78733,"source":{"system":"sec-edgar","filing":"0001600620-23-000019","document":"wk-form4_1684876599.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000160062023000019/wk-form4_1684876599.xml","form_type":"4"}},{"id":1944856,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T00:25:57.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":1916,"price":32.4487,"value":62171.7092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.30 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":862021,"source":{"system":"sec-edgar","filing":"0000899243-23-009179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323009179/doc4.xml","form_type":"4"}},{"id":1944855,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-21T00:25:57.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":33084,"price":31.8553,"value":1053900.7452,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 16, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.30 to $32.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":863937,"source":{"system":"sec-edgar","filing":"0000899243-23-009179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323009179/doc4.xml","form_type":"4"}},{"id":1969550,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-06T21:29:53.000Z","date":"2023-03-02","kind":"purchase","acquired":true,"shares":20000,"price":8.9142,"value":178284.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $8.86 to $8.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001628280-23-006533","document":"wf-form4_167813818041525.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828023006533/wf-form4_167813818041525.xml","form_type":"4"}},{"id":2017011,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-2 Preferred Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":23212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23212},"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2017010,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C-1 Preferred Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":19482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19482},"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2017009,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":384449,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":384449},"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2017008,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-01-06","kind":"exercise","acquired":false,"shares":262282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":262282},"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2017007,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-12-29","kind":"gift","acquired":false,"shares":13800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":897021,"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2017006,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-14T21:35:32.000Z","date":"2022-01-06","kind":"exercise","acquired":true,"shares":689425,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series A, Series B, Series C-1 and Series C-2 Preferred Stock (the \"Preferred Stock\") automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Preferred Stock had no expiration date."}],"balance_after":910821,"source":{"system":"sec-edgar","filing":"0000899243-23-004990","document":"doc5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924323004990/doc5.xml","form_type":"5"}},{"id":2236435,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:05:30.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director."}],"balance_after":19000,"derivative":{"exercise_price":13.56,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0000899243-22-021889","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924322021889/doc4.xml","form_type":"4"}},{"id":2262168,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-20T20:10:57.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":14612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in twelve equal monthly installments commencing on June 18, 2022."}],"balance_after":14612,"derivative":{"exercise_price":11.45,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":14612},"source":{"system":"sec-edgar","filing":"0001628280-22-015035","document":"wf-form4_165307739688602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828022015035/wf-form4_165307739688602.xml","form_type":"4"}},{"id":2262167,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-20T20:10:57.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":8733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of the Issuers common stock. The RSUs will vest and be delivered to the Reporting Person one year from date of grant."}],"balance_after":8733,"derivative":{"underlying":"Common Shares","underlying_shares":8733},"source":{"system":"sec-edgar","filing":"0001628280-22-015035","document":"wf-form4_165307739688602.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828022015035/wf-form4_165307739688602.xml","form_type":"4"}},{"id":2344978,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-08T21:06:37.000Z","date":"2022-03-04","kind":"purchase","acquired":true,"shares":5000,"price":10.82,"value":54100.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.81 to $10.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001628280-22-005381","document":"wf-form4_164677357726147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828022005381/wf-form4_164677357726147.xml","form_type":"4"}},{"id":2439038,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-11T01:34:15.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":8400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":8400,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":8400},"source":{"system":"sec-edgar","filing":"0000899243-22-001521","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924322001521/doc4.xml","form_type":"4"}},{"id":2439037,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T01:34:15.000Z","date":"2022-01-06","kind":"purchase","acquired":true,"shares":26315,"price":19,"value":499985.0,"ownership":{"direct":true},"balance_after":221396,"source":{"system":"sec-edgar","filing":"0000899243-22-001521","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000089924322001521/doc4.xml","form_type":"4"}},{"id":2666677,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-17T01:20:28.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":31347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing on July 14, 2021."}],"balance_after":31347,"derivative":{"exercise_price":12.86,"expiration_date":"2031-06-14","underlying":"Stock Option (right to buy)","underlying_shares":31347},"source":{"system":"sec-edgar","filing":"0001628280-21-012386","document":"wf-form4_162389281306609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828021012386/wf-form4_162389281306609.xml","form_type":"4"}},{"id":2721347,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2021-05-10T21:39:56.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":1151,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The Stock Options become exercisable upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":1151,"derivative":{"exercise_price":342.55,"exercise_date":"2022-05-07","expiration_date":"2031-05-07","underlying":"Common Stock","underlying_shares":1151},"source":{"system":"sec-edgar","filing":"0001127602-21-016113","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016113/form4.xml","form_type":"4"}},{"id":2721346,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-10T21:39:56.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 5, 2021. The restricted stock units vest upon the earlier of 5/7/2022, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":29079,"source":{"system":"sec-edgar","filing":"0001127602-21-016113","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016113/form4.xml","form_type":"4"}},{"id":2721345,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-05-10T21:39:56.000Z","date":"2021-05-07","kind":"grant","acquired":true,"shares":355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/7/2022 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":28772,"source":{"system":"sec-edgar","filing":"0001127602-21-016113","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221016113/form4.xml","form_type":"4"}},{"id":2800328,"issuer":{"id":4463,"kind":"organization","name":"Aurinia Pharmaceuticals Inc.","symbol":"AUPH"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-03-09T21:25:08.000Z","date":"2021-03-05","kind":"purchase","acquired":true,"shares":5000,"price":13,"value":65000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $12.995 to $13.00, inclusive.  The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001628280-21-004265","document":"wf-form4_161532509442005.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1179552/000162828021004265/wf-form4_161532509442005.xml","form_type":"4"}},{"id":2821498,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2021-03-02T21:47:00.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":3530,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":52.29,"exercise_date":"2015-05-07","expiration_date":"2021-05-07","underlying":"Common Stock","underlying_shares":3530},"source":{"system":"sec-edgar","filing":"0001127602-21-008742","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221008742/form4.xml","form_type":"4"}},{"id":2821497,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-02T21:47:00.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":3530,"price":290.0085,"value":1023730.005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $290.00 to $290.175. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":28417,"source":{"system":"sec-edgar","filing":"0001127602-21-008742","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221008742/form4.xml","form_type":"4"}},{"id":2821496,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-03-02T21:47:00.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":3530,"price":52.29,"value":184583.7,"ownership":{"direct":true},"balance_after":31947,"source":{"system":"sec-edgar","filing":"0001127602-21-008742","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760221008742/form4.xml","form_type":"4"}},{"id":3153073,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2020-05-12T18:23:07.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":2539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Stock Options become exercisable upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":2539,"derivative":{"exercise_price":164.24,"exercise_date":"2021-05-11","expiration_date":"2030-05-11","underlying":"Common Stock","underlying_shares":2539},"source":{"system":"sec-edgar","filing":"0001127602-20-016255","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016255/form4.xml","form_type":"4"}},{"id":3153072,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-12T18:23:07.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":639,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The grant was made in lieu of director service fees for the term commencing May 6, 2020.  The restricted stock units vest upon the earlier of 5/11/2021, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":28417,"source":{"system":"sec-edgar","filing":"0001127602-20-016255","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016255/form4.xml","form_type":"4"}},{"id":3153071,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-05-12T18:23:07.000Z","date":"2020-05-11","kind":"grant","acquired":true,"shares":741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The unvested restricted stock units vest upon the earlier of 5/11/2021 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":27778,"source":{"system":"sec-edgar","filing":"0001127602-20-016255","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220016255/form4.xml","form_type":"4"}},{"id":3264079,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2020-02-19T15:41:26.000Z","date":"2020-02-18","kind":"exercise","acquired":false,"shares":3140,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":70.29,"exercise_date":"2016-05-06","expiration_date":"2020-05-06","underlying":"Common Stock","underlying_shares":3140},"source":{"system":"sec-edgar","filing":"0001127602-20-006257","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220006257/form4.xml","form_type":"4"}},{"id":3264078,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2020-02-19T15:41:26.000Z","date":"2020-02-18","kind":"exercise","acquired":false,"shares":4030,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":43.39,"exercise_date":"2014-05-08","expiration_date":"2020-05-08","underlying":"Common Stock","underlying_shares":4030},"source":{"system":"sec-edgar","filing":"0001127602-20-006257","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220006257/form4.xml","form_type":"4"}},{"id":3264077,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-19T15:41:26.000Z","date":"2020-02-18","kind":"sale","acquired":false,"shares":7170,"price":176.0711,"value":1262429.787,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $175.70 to $176.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":27037,"source":{"system":"sec-edgar","filing":"0001127602-20-006257","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220006257/form4.xml","form_type":"4"}},{"id":3264076,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-19T15:41:26.000Z","date":"2020-02-18","kind":"exercise","acquired":true,"shares":3140,"price":70.29,"value":220710.6,"ownership":{"direct":true},"balance_after":34207,"source":{"system":"sec-edgar","filing":"0001127602-20-006257","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220006257/form4.xml","form_type":"4"}},{"id":3264075,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2020-02-19T15:41:26.000Z","date":"2020-02-18","kind":"exercise","acquired":true,"shares":4030,"price":43.39,"value":174861.7,"ownership":{"direct":true},"balance_after":31067,"source":{"system":"sec-edgar","filing":"0001127602-20-006257","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760220006257/form4.xml","form_type":"4"}},{"id":3513748,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-23T17:30:49.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":812,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of director service fees for the term commencing May 21, 2019.  The restricted stock units vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":27037,"source":{"system":"sec-edgar","filing":"0001127602-19-019572","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219019572/form4.xml","form_type":"4"}},{"id":3513747,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-05-23T17:30:49.000Z","date":"2019-05-22","kind":"grant","acquired":true,"shares":1882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 1,882 unvested restricted stock units that vest upon the earlier of 5/22/2020, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":26225,"source":{"system":"sec-edgar","filing":"0001127602-19-019572","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219019572/form4.xml","form_type":"4"}},{"id":3636347,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2019-02-25T15:12:36.000Z","date":"2019-02-22","kind":"exercise","acquired":false,"shares":4540,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":33.93,"exercise_date":"2013-05-09","expiration_date":"2019-05-09","underlying":"Common Stock","underlying_shares":4540},"source":{"system":"sec-edgar","filing":"0001127602-19-007889","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219007889/form4.xml","form_type":"4"}},{"id":3636346,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-25T15:12:36.000Z","date":"2019-02-22","kind":"sale","acquired":false,"shares":4540,"price":143,"value":649220.0,"ownership":{"direct":true},"balance_after":24343,"source":{"system":"sec-edgar","filing":"0001127602-19-007889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219007889/form4.xml","form_type":"4"}},{"id":3636345,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-25T15:12:36.000Z","date":"2019-02-22","kind":"exercise","acquired":true,"shares":4540,"price":33.93,"value":154042.2,"ownership":{"direct":true},"balance_after":28883,"source":{"system":"sec-edgar","filing":"0001127602-19-007889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219007889/form4.xml","form_type":"4"}},{"id":3679868,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-02-01T18:08:19.000Z","date":"2018-12-03","kind":"gift","acquired":false,"shares":5240,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":24343,"source":{"system":"sec-edgar","filing":"0001127602-19-003337","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760219003337/form5.xml","form_type":"5"}},{"id":3933282,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-15T20:14:18.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of director service fees for the term commencing May 8, 2018.  The restricted stock units vest upon the earlier of 5/14/2019 or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":29583,"source":{"system":"sec-edgar","filing":"0001127602-18-017521","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218017521/form4.xml","form_type":"4"}},{"id":3933281,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-15T20:14:18.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":2004,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 2,004 unvested restricted stock units that vest upon the earlier of 5/14/2019, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":28744,"source":{"system":"sec-edgar","filing":"0001127602-18-017521","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218017521/form4.xml","form_type":"4"}},{"id":3933280,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-05-15T20:14:18.000Z","date":"2018-03-13","kind":"gift","acquired":false,"shares":2280,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":26740,"source":{"system":"sec-edgar","filing":"0001127602-18-017521","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218017521/form4.xml","form_type":"4"}},{"id":3998770,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2018-03-13T15:43:43.000Z","date":"2018-03-09","kind":"exercise","acquired":false,"shares":7740,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":40.27,"exercise_date":"2012-05-11","expiration_date":"2018-05-11","underlying":"Common Stock","underlying_shares":7740},"source":{"system":"sec-edgar","filing":"0001127602-18-011328","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218011328/form4.xml","form_type":"4"}},{"id":3998769,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-03-13T15:43:43.000Z","date":"2018-03-09","kind":"sale","acquired":false,"shares":7740,"price":115,"value":890100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale occurred pursuant to a 10b5-1 Trading Plan."}],"balance_after":29020,"source":{"system":"sec-edgar","filing":"0001127602-18-011328","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218011328/form4.xml","form_type":"4"}},{"id":3998768,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-03-13T15:43:43.000Z","date":"2018-03-09","kind":"exercise","acquired":true,"shares":7740,"price":40.27,"value":311689.8,"ownership":{"direct":true},"balance_after":36760,"source":{"system":"sec-edgar","filing":"0001127602-18-011328","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218011328/form4.xml","form_type":"4"}},{"id":4074078,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2018-02-06T23:46:36.000Z","date":"2017-12-05","kind":"gift","acquired":false,"shares":2980,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":29020,"source":{"system":"sec-edgar","filing":"0001127602-18-004392","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760218004392/form5.xml","form_type":"5"}},{"id":4318733,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-05-16T10:36:32.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":1034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This grant was made in lieu of director service fees for the term commencing May 9, 2017, and includes an increase to the fee he receives for being Lead Independent Director, which was effective at the beginning of 2017.  The restricted stock units vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001127602-17-018162","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217018162/form4.xml","form_type":"4"}},{"id":4318732,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-05-16T10:36:32.000Z","date":"2017-05-12","kind":"grant","acquired":true,"shares":2436,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Consists of 2,436 unvested restricted stock units that vest upon the earlier of 5/12/2018, or the business day prior to the Company's next annual meeting of shareholders."}],"balance_after":30966,"source":{"system":"sec-edgar","filing":"0001127602-17-018162","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217018162/form4.xml","form_type":"4"}},{"id":4446139,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Stock Options (Right to Buy)","published_at":"2017-02-15T19:39:16.000Z","date":"2017-02-14","kind":"exercise","acquired":false,"shares":10710,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":30.44,"exercise_date":"2011-05-07","expiration_date":"2017-05-07","underlying":"Common Stock","underlying_shares":10710},"source":{"system":"sec-edgar","filing":"0001127602-17-006234","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217006234/form4.xml","form_type":"4"}},{"id":4446138,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-02-15T19:39:16.000Z","date":"2017-02-14","kind":"sale","acquired":false,"shares":10710,"price":86.52,"value":926629.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale occurred pursuant to a 10b5-1 Trading Plan."}],"balance_after":28530,"source":{"system":"sec-edgar","filing":"0001127602-17-006234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217006234/form4.xml","form_type":"4"}},{"id":4446137,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-02-15T19:39:16.000Z","date":"2017-02-14","kind":"exercise","acquired":true,"shares":10710,"price":30.44,"value":326012.4,"ownership":{"direct":true},"balance_after":39240,"source":{"system":"sec-edgar","filing":"0001127602-17-006234","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217006234/form4.xml","form_type":"4"}},{"id":4484238,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":40611,"kind":"person","name":"MILNE GEORGE M JR","position":1,"cik":"0001179552","reported_name":"MILNE GEORGE M JR","relationship":{"director":true}}],"security":"Common Stock","published_at":"2017-01-23T14:52:51.000Z","date":"2016-12-05","kind":"gift","acquired":false,"shares":2530,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28530,"source":{"system":"sec-edgar","filing":"0001127602-17-002205","document":"form5.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760217002205/form5.xml","form_type":"5"}}]}